Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Diseases | 28 | 2021 | 443 | 2.060 |
Why?
|
Breast | 38 | 2021 | 1963 | 1.300 |
Why?
|
Breast Neoplasms | 121 | 2021 | 20981 | 1.250 |
Why?
|
Carcinoma, Ductal, Breast | 21 | 2017 | 1084 | 0.760 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 32 | 2014 | 926 | 0.720 |
Why?
|
Tomography, Optical Coherence | 9 | 2017 | 2923 | 0.630 |
Why?
|
Carcinoma in Situ | 15 | 2005 | 791 | 0.580 |
Why?
|
Mastectomy, Segmental | 19 | 2017 | 955 | 0.460 |
Why?
|
Pathology, Surgical | 3 | 2009 | 151 | 0.380 |
Why?
|
Cancer Care Facilities | 3 | 2020 | 422 | 0.380 |
Why?
|
Neoplasm Recurrence, Local | 40 | 2019 | 9278 | 0.360 |
Why?
|
Adenoma, Oxyphilic | 1 | 2011 | 148 | 0.350 |
Why?
|
Fibrocystic Breast Disease | 7 | 2013 | 103 | 0.330 |
Why?
|
Neoplasm Staging | 19 | 2017 | 11118 | 0.320 |
Why?
|
Bone Diseases, Infectious | 1 | 2007 | 16 | 0.280 |
Why?
|
Microscopy | 4 | 2014 | 904 | 0.280 |
Why?
|
Pathology, Clinical | 5 | 2010 | 376 | 0.250 |
Why?
|
Aspergillus fumigatus | 1 | 2007 | 157 | 0.250 |
Why?
|
Lymphatic Metastasis | 15 | 2017 | 2913 | 0.250 |
Why?
|
Aspergillosis | 1 | 2007 | 242 | 0.240 |
Why?
|
Microscopy, Confocal | 3 | 2017 | 1967 | 0.240 |
Why?
|
Mastectomy | 11 | 2019 | 1817 | 0.230 |
Why?
|
Accreditation | 2 | 2019 | 473 | 0.230 |
Why?
|
Thyroid Neoplasms | 5 | 2016 | 2331 | 0.230 |
Why?
|
Hearing Tests | 1 | 2005 | 121 | 0.230 |
Why?
|
Interferometry | 1 | 2004 | 100 | 0.230 |
Why?
|
Carcinoma | 10 | 2016 | 2328 | 0.220 |
Why?
|
Evoked Potentials, Auditory, Brain Stem | 1 | 2005 | 253 | 0.220 |
Why?
|
Problem Solving | 1 | 2006 | 443 | 0.220 |
Why?
|
Carcinoma, Lobular | 5 | 2017 | 480 | 0.210 |
Why?
|
Temporal Bone | 1 | 2007 | 683 | 0.200 |
Why?
|
Thyroid Gland | 2 | 2010 | 1170 | 0.190 |
Why?
|
Immunocompromised Host | 1 | 2007 | 858 | 0.190 |
Why?
|
Biopsy | 24 | 2015 | 6781 | 0.180 |
Why?
|
Practice Guidelines as Topic | 6 | 2019 | 7400 | 0.180 |
Why?
|
Neonatal Screening | 1 | 2005 | 597 | 0.170 |
Why?
|
Neoplasms, Multiple Primary | 5 | 2000 | 592 | 0.170 |
Why?
|
Female | 133 | 2021 | 392458 | 0.170 |
Why?
|
Biopsy, Needle | 5 | 2004 | 1624 | 0.160 |
Why?
|
Imaging, Three-Dimensional | 3 | 2017 | 4060 | 0.160 |
Why?
|
Microscopy, Ultraviolet | 1 | 2018 | 3 | 0.160 |
Why?
|
Parathyroid Neoplasms | 2 | 2011 | 242 | 0.150 |
Why?
|
Precancerous Conditions | 6 | 2012 | 982 | 0.150 |
Why?
|
Prognosis | 28 | 2020 | 29672 | 0.150 |
Why?
|
Combined Modality Therapy | 29 | 2005 | 8519 | 0.150 |
Why?
|
Middle Aged | 77 | 2021 | 220835 | 0.150 |
Why?
|
Hyperplasia | 12 | 2015 | 1150 | 0.140 |
Why?
|
Hearing Loss | 1 | 2005 | 782 | 0.140 |
Why?
|
Transillumination | 1 | 2016 | 20 | 0.140 |
Why?
|
Humans | 148 | 2021 | 761098 | 0.140 |
Why?
|
Alcohol Drinking | 5 | 2013 | 4028 | 0.140 |
Why?
|
Societies, Medical | 5 | 2009 | 3923 | 0.140 |
Why?
|
Hematoxylin | 1 | 2016 | 60 | 0.140 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2016 | 69 | 0.140 |
Why?
|
Adult | 69 | 2021 | 221083 | 0.140 |
Why?
|
Carcinoma, Renal Cell | 1 | 2011 | 3163 | 0.130 |
Why?
|
Lymph Nodes | 5 | 2009 | 3461 | 0.130 |
Why?
|
Specimen Handling | 2 | 2009 | 701 | 0.130 |
Why?
|
Menarche | 2 | 2021 | 532 | 0.130 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 4251 | 0.120 |
Why?
|
Microscopy, Fluorescence, Multiphoton | 1 | 2016 | 267 | 0.120 |
Why?
|
Image Enhancement | 3 | 2013 | 2888 | 0.110 |
Why?
|
Thyroid Diseases | 2 | 2010 | 386 | 0.110 |
Why?
|
Axilla | 8 | 2001 | 624 | 0.110 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2016 | 3367 | 0.110 |
Why?
|
Diagnosis, Differential | 8 | 2016 | 12975 | 0.110 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2012 | 1932 | 0.110 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2012 | 415 | 0.100 |
Why?
|
Microscopy, Fluorescence | 2 | 2017 | 2637 | 0.100 |
Why?
|
Risk Factors | 32 | 2021 | 74219 | 0.100 |
Why?
|
Neoplasm Invasiveness | 10 | 2017 | 3591 | 0.100 |
Why?
|
Calcinosis | 5 | 2004 | 1477 | 0.100 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2016 | 323 | 0.100 |
Why?
|
Aged | 40 | 2021 | 169266 | 0.100 |
Why?
|
Nonlinear Dynamics | 1 | 2014 | 492 | 0.100 |
Why?
|
Adenoma | 2 | 2016 | 2159 | 0.090 |
Why?
|
Lighting | 1 | 2013 | 211 | 0.090 |
Why?
|
Molecular Typing | 1 | 2011 | 116 | 0.090 |
Why?
|
Spinal Diseases | 1 | 2016 | 562 | 0.090 |
Why?
|
Technetium Tc 99m Sestamibi | 2 | 2002 | 183 | 0.090 |
Why?
|
Carcinoma, Papillary | 3 | 2016 | 785 | 0.090 |
Why?
|
Pattern Recognition, Automated | 1 | 2017 | 993 | 0.090 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2011 | 163 | 0.090 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2018 | 9001 | 0.090 |
Why?
|
Receptors, Progesterone | 6 | 2011 | 1129 | 0.090 |
Why?
|
Dietary Fiber | 3 | 2010 | 758 | 0.090 |
Why?
|
Diet | 4 | 2014 | 8047 | 0.080 |
Why?
|
Molecular Probe Techniques | 1 | 2010 | 111 | 0.080 |
Why?
|
Hyperparathyroidism | 1 | 2011 | 337 | 0.080 |
Why?
|
Lasers | 1 | 2013 | 952 | 0.080 |
Why?
|
Odds Ratio | 10 | 2015 | 9648 | 0.080 |
Why?
|
Quality Indicators, Health Care | 1 | 2019 | 1790 | 0.080 |
Why?
|
Tissue Array Analysis | 4 | 2011 | 550 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 208 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2011 | 242 | 0.080 |
Why?
|
Histocytochemistry | 1 | 2010 | 697 | 0.080 |
Why?
|
Receptor, IGF Type 1 | 1 | 2011 | 380 | 0.080 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5809 | 0.080 |
Why?
|
Mammography | 10 | 2004 | 2430 | 0.080 |
Why?
|
Adenocarcinoma | 4 | 2004 | 6340 | 0.080 |
Why?
|
Nuts | 1 | 2010 | 264 | 0.070 |
Why?
|
Ganglia, Sympathetic | 1 | 1987 | 65 | 0.070 |
Why?
|
Receptors, Estrogen | 7 | 2011 | 2208 | 0.070 |
Why?
|
Parity | 3 | 2021 | 924 | 0.070 |
Why?
|
Sensitivity and Specificity | 9 | 2017 | 14676 | 0.070 |
Why?
|
Proportional Hazards Models | 10 | 2014 | 12467 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4245 | 0.070 |
Why?
|
Case-Control Studies | 12 | 2021 | 22157 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2016 | 2218 | 0.070 |
Why?
|
Gold | 1 | 2010 | 482 | 0.070 |
Why?
|
Cohort Studies | 14 | 2021 | 41486 | 0.070 |
Why?
|
Manuals as Topic | 1 | 2006 | 99 | 0.060 |
Why?
|
Lymph Node Excision | 6 | 2004 | 1269 | 0.060 |
Why?
|
Intestine, Large | 1 | 2005 | 69 | 0.060 |
Why?
|
Reproductive History | 2 | 2013 | 210 | 0.060 |
Why?
|
Disease-Free Survival | 4 | 2005 | 6817 | 0.060 |
Why?
|
Histological Techniques | 2 | 2018 | 193 | 0.060 |
Why?
|
Folic Acid | 1 | 2012 | 1323 | 0.060 |
Why?
|
Mississippi | 1 | 2005 | 94 | 0.060 |
Why?
|
Quality Control | 2 | 2019 | 834 | 0.060 |
Why?
|
Risk | 10 | 2012 | 9614 | 0.060 |
Why?
|
Neurosurgical Procedures | 1 | 2016 | 2067 | 0.060 |
Why?
|
Incidence | 11 | 2016 | 21357 | 0.060 |
Why?
|
Coloring Agents | 2 | 2017 | 562 | 0.060 |
Why?
|
Ultrasonography, Mammary | 2 | 2004 | 239 | 0.060 |
Why?
|
Ear, Middle | 1 | 2007 | 339 | 0.060 |
Why?
|
Stereotaxic Techniques | 2 | 2004 | 555 | 0.060 |
Why?
|
Nerve Growth Factors | 1 | 1987 | 564 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4013 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2007 | 20600 | 0.060 |
Why?
|
Dietary Fats | 3 | 2014 | 1995 | 0.060 |
Why?
|
Parathyroid Hormone | 1 | 2011 | 1803 | 0.060 |
Why?
|
Aged, 80 and over | 12 | 2016 | 58946 | 0.060 |
Why?
|
Equipment Design | 3 | 2018 | 3509 | 0.060 |
Why?
|
Keratins | 4 | 2008 | 498 | 0.060 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 834 | 0.060 |
Why?
|
Microtomy | 2 | 1997 | 44 | 0.050 |
Why?
|
United States | 17 | 2017 | 72337 | 0.050 |
Why?
|
Necrosis | 2 | 2007 | 1611 | 0.050 |
Why?
|
Retrospective Studies | 21 | 2020 | 80673 | 0.050 |
Why?
|
Sampling Studies | 1 | 2004 | 615 | 0.050 |
Why?
|
Menopause | 4 | 2021 | 1646 | 0.050 |
Why?
|
Fibroadenoma | 1 | 2002 | 41 | 0.050 |
Why?
|
Prospective Studies | 18 | 2015 | 54419 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2007 | 1837 | 0.050 |
Why?
|
Immunohistochemistry | 4 | 2018 | 11066 | 0.050 |
Why?
|
Calcium | 2 | 2012 | 5720 | 0.050 |
Why?
|
Neoplasm Metastasis | 6 | 2017 | 4908 | 0.050 |
Why?
|
Medical Records | 2 | 2009 | 1409 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 1997 | 1008 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2011 | 3512 | 0.050 |
Why?
|
Clinical Protocols | 4 | 2009 | 1436 | 0.050 |
Why?
|
Radiopharmaceuticals | 2 | 2002 | 2682 | 0.050 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2006 | 732 | 0.050 |
Why?
|
Keratin-5 | 2 | 2011 | 45 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4583 | 0.050 |
Why?
|
Follow-Up Studies | 21 | 2020 | 39121 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2011 | 3493 | 0.050 |
Why?
|
Specialty Boards | 1 | 2003 | 235 | 0.050 |
Why?
|
Estrogen Replacement Therapy | 2 | 2013 | 1208 | 0.050 |
Why?
|
Predictive Value of Tests | 8 | 2021 | 15308 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2010 | 5249 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 4 | 1999 | 2820 | 0.040 |
Why?
|
Reproducibility of Results | 5 | 2017 | 20120 | 0.040 |
Why?
|
Autopsy | 1 | 2004 | 1010 | 0.040 |
Why?
|
Observer Variation | 4 | 2004 | 2611 | 0.040 |
Why?
|
Lymphatic Irradiation | 1 | 2000 | 115 | 0.040 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1265 | 0.040 |
Why?
|
Pathology | 1 | 2003 | 269 | 0.040 |
Why?
|
Algorithms | 2 | 2017 | 14023 | 0.040 |
Why?
|
Intestine, Small | 1 | 2005 | 1207 | 0.040 |
Why?
|
Sarcoma, Kaposi | 1 | 2002 | 374 | 0.040 |
Why?
|
Bone Marrow Transplantation | 1 | 2007 | 2692 | 0.040 |
Why?
|
Actuarial Analysis | 4 | 1994 | 372 | 0.040 |
Why?
|
Elasticity | 1 | 2021 | 655 | 0.040 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2002 | 662 | 0.040 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2005 | 781 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4565 | 0.040 |
Why?
|
Vitamin D | 1 | 2012 | 3302 | 0.040 |
Why?
|
Nanoparticles | 1 | 2010 | 1959 | 0.040 |
Why?
|
Acridine Orange | 1 | 2017 | 28 | 0.040 |
Why?
|
Light | 1 | 2004 | 1351 | 0.040 |
Why?
|
Gene Expression | 1 | 2011 | 7567 | 0.040 |
Why?
|
Body Size | 1 | 2021 | 463 | 0.040 |
Why?
|
Mammary Neoplasms, Experimental | 2 | 1996 | 506 | 0.040 |
Why?
|
Adolescent | 11 | 2016 | 88271 | 0.040 |
Why?
|
Risk Assessment | 5 | 2021 | 24013 | 0.040 |
Why?
|
Rhodamines | 1 | 2017 | 178 | 0.040 |
Why?
|
Radiotherapy Dosage | 3 | 2004 | 2898 | 0.040 |
Why?
|
Nurses | 4 | 2013 | 2476 | 0.040 |
Why?
|
Analysis of Variance | 3 | 2021 | 6224 | 0.030 |
Why?
|
Treatment Failure | 2 | 2000 | 2643 | 0.030 |
Why?
|
Contrast Media | 1 | 2010 | 5311 | 0.030 |
Why?
|
Internship and Residency | 2 | 2010 | 5879 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2017 | 510 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2011 | 9416 | 0.030 |
Why?
|
Treatment Outcome | 12 | 2011 | 64670 | 0.030 |
Why?
|
Receptor, erbB-2 | 3 | 2011 | 2553 | 0.030 |
Why?
|
Gelsolin | 1 | 1996 | 189 | 0.030 |
Why?
|
Surgery, Computer-Assisted | 1 | 2004 | 1004 | 0.030 |
Why?
|
Vitamins | 1 | 2004 | 1634 | 0.030 |
Why?
|
HIV Infections | 1 | 2002 | 17349 | 0.030 |
Why?
|
Adiposity | 1 | 2005 | 1879 | 0.030 |
Why?
|
Neoplasms | 3 | 2005 | 22125 | 0.030 |
Why?
|
Palpation | 2 | 2004 | 166 | 0.030 |
Why?
|
Regression Analysis | 5 | 2010 | 6343 | 0.030 |
Why?
|
Carcinoma, Medullary | 2 | 2007 | 115 | 0.030 |
Why?
|
Adolescent Behavior | 1 | 2003 | 1188 | 0.030 |
Why?
|
Premenopause | 2 | 2012 | 1038 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2002 | 1372 | 0.030 |
Why?
|
Retroelements | 1 | 1996 | 162 | 0.030 |
Why?
|
Exercise | 1 | 2011 | 5872 | 0.030 |
Why?
|
Genetic Variation | 1 | 2010 | 6565 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2005 | 2757 | 0.030 |
Why?
|
Genomics | 1 | 2010 | 5828 | 0.030 |
Why?
|
Survival Rate | 4 | 2010 | 12727 | 0.030 |
Why?
|
Receptors, Growth Factor | 1 | 1995 | 325 | 0.030 |
Why?
|
Young Adult | 4 | 2016 | 59199 | 0.030 |
Why?
|
Time Factors | 10 | 2013 | 39953 | 0.030 |
Why?
|
Carbon | 1 | 1997 | 665 | 0.030 |
Why?
|
Software | 1 | 2007 | 4433 | 0.030 |
Why?
|
Cicatrix | 1 | 1999 | 793 | 0.030 |
Why?
|
Estrogens | 1 | 1999 | 1521 | 0.030 |
Why?
|
Salvage Therapy | 2 | 2005 | 1264 | 0.030 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2004 | 517 | 0.030 |
Why?
|
Endothelial Growth Factors | 1 | 1995 | 672 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2020 | 26068 | 0.020 |
Why?
|
Keratin-6 | 1 | 2011 | 17 | 0.020 |
Why?
|
Lymphokines | 1 | 1995 | 925 | 0.020 |
Why?
|
Micronutrients | 1 | 2014 | 381 | 0.020 |
Why?
|
Cytoplasm | 2 | 2011 | 1498 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2004 | 3410 | 0.020 |
Why?
|
Multivariate Analysis | 4 | 2012 | 12058 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2013 | 846 | 0.020 |
Why?
|
Logistic Models | 4 | 2010 | 13254 | 0.020 |
Why?
|
Nutritional Requirements | 1 | 2012 | 274 | 0.020 |
Why?
|
Subrenal Capsule Assay | 1 | 1990 | 27 | 0.020 |
Why?
|
Body Mass Index | 3 | 2021 | 12951 | 0.020 |
Why?
|
Hybrid Cells | 1 | 1990 | 421 | 0.020 |
Why?
|
Immunoenzyme Techniques | 2 | 2010 | 1703 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2004 | 3535 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2002 | 3309 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2017 | 1902 | 0.020 |
Why?
|
Cell Fusion | 1 | 1990 | 294 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3582 | 0.020 |
Why?
|
Women's Health | 3 | 2004 | 2068 | 0.020 |
Why?
|
Epithelial Cells | 2 | 1998 | 3666 | 0.020 |
Why?
|
Neurons | 1 | 1987 | 9435 | 0.020 |
Why?
|
Double-Blind Method | 2 | 1992 | 12341 | 0.020 |
Why?
|
Adrenal Medulla | 1 | 1987 | 56 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 2 | 1987 | 944 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2873 | 0.020 |
Why?
|
Age Factors | 6 | 2005 | 18385 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1995 | 1624 | 0.020 |
Why?
|
Radionuclide Imaging | 2 | 2002 | 1989 | 0.020 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 1987 | 179 | 0.020 |
Why?
|
Family Health | 2 | 2006 | 1255 | 0.020 |
Why?
|
S100 Proteins | 1 | 1987 | 216 | 0.020 |
Why?
|
Chromogranins | 1 | 1987 | 160 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2004 | 1784 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 1993 | 1051 | 0.020 |
Why?
|
Lipoma | 1 | 1987 | 293 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2006 | 17889 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2005 | 26187 | 0.010 |
Why?
|
Postmenopause | 1 | 2013 | 2511 | 0.010 |
Why?
|
Epithelium | 3 | 1999 | 1603 | 0.010 |
Why?
|
Male | 7 | 2020 | 360675 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 1996 | 3594 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2714 | 0.010 |
Why?
|
Hot Temperature | 1 | 2010 | 1434 | 0.010 |
Why?
|
Cell Membrane | 2 | 2011 | 3665 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9324 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 1520 | 0.010 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2010 | 955 | 0.010 |
Why?
|
Biopsy, Fine-Needle | 1 | 2007 | 1118 | 0.010 |
Why?
|
Transfection | 1 | 1990 | 5750 | 0.010 |
Why?
|
Health Surveys | 1 | 2012 | 4036 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 1987 | 732 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 1993 | 11732 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2004 | 958 | 0.010 |
Why?
|
Thyroidectomy | 1 | 2007 | 908 | 0.010 |
Why?
|
Radiotherapy | 4 | 1990 | 1498 | 0.010 |
Why?
|
Genes, erbB | 1 | 2000 | 5 | 0.010 |
Why?
|
Diet Surveys | 1 | 2004 | 1161 | 0.010 |
Why?
|
Meningioma | 1 | 1989 | 1216 | 0.010 |
Why?
|
Ploidies | 1 | 2000 | 285 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10755 | 0.010 |
Why?
|
Meningeal Neoplasms | 1 | 1989 | 1246 | 0.010 |
Why?
|
Certification | 1 | 2003 | 418 | 0.010 |
Why?
|
Cell Nucleus | 2 | 2005 | 2881 | 0.010 |
Why?
|
Survival Analysis | 3 | 2000 | 10083 | 0.010 |
Why?
|
Child | 1 | 2007 | 80134 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 1996 | 9566 | 0.010 |
Why?
|
Pregnancy | 2 | 2013 | 29872 | 0.010 |
Why?
|
Vegetables | 1 | 2003 | 1192 | 0.010 |
Why?
|
Genes, p53 | 1 | 2000 | 713 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1996 | 11856 | 0.010 |
Why?
|
Rats | 2 | 1996 | 23713 | 0.010 |
Why?
|
Radiation Injuries | 1 | 1984 | 1191 | 0.010 |
Why?
|
Curriculum | 1 | 2010 | 3739 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2004 | 36418 | 0.010 |
Why?
|
Phospholipase D | 1 | 1996 | 67 | 0.010 |
Why?
|
Cell Division | 2 | 1997 | 4451 | 0.010 |
Why?
|
Teratocarcinoma | 1 | 1996 | 16 | 0.010 |
Why?
|
Antioxidants | 1 | 2004 | 1667 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 1996 | 6123 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2002 | 3419 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 1996 | 914 | 0.010 |
Why?
|
Blotting, Western | 2 | 1996 | 5033 | 0.010 |
Why?
|
Mitosis | 1 | 2000 | 1186 | 0.010 |
Why?
|
Mammary Glands, Animal | 1 | 1996 | 272 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2000 | 1743 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 1987 | 4405 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 1988 | 9185 | 0.010 |
Why?
|
Clinical Competence | 1 | 2010 | 4786 | 0.010 |
Why?
|
World Health Organization | 1 | 2000 | 1321 | 0.010 |
Why?
|
Stromal Cells | 1 | 1999 | 1329 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1987 | 18926 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2000 | 2424 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1995 | 748 | 0.010 |
Why?
|
Mutagenesis, Insertional | 1 | 1996 | 657 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1997 | 2927 | 0.010 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 1995 | 664 | 0.010 |
Why?
|
Family | 1 | 2002 | 3193 | 0.010 |
Why?
|
Prevalence | 1 | 2008 | 15717 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2000 | 2802 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1995 | 1900 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1996 | 12743 | 0.010 |
Why?
|
Phenotype | 1 | 2008 | 16572 | 0.010 |
Why?
|
Radioisotope Teletherapy | 1 | 1989 | 15 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 15915 | 0.010 |
Why?
|
Actins | 1 | 1996 | 2046 | 0.010 |
Why?
|
Esthetics | 1 | 1991 | 327 | 0.000 |
Why?
|
Adenofibroma | 1 | 1987 | 25 | 0.000 |
Why?
|
Brain Neoplasms | 1 | 1989 | 9025 | 0.000 |
Why?
|
Mice, Inbred BALB C | 1 | 1996 | 6198 | 0.000 |
Why?
|
Ganglioneuroma | 1 | 1987 | 53 | 0.000 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1624 | 0.000 |
Why?
|
Molecular Weight | 1 | 1988 | 2171 | 0.000 |
Why?
|
Smoking | 1 | 2002 | 9055 | 0.000 |
Why?
|
Rats, Sprague-Dawley | 1 | 1996 | 8164 | 0.000 |
Why?
|
Pheochromocytoma | 1 | 1987 | 328 | 0.000 |
Why?
|
Animals | 4 | 1996 | 168083 | 0.000 |
Why?
|
Postoperative Period | 1 | 1990 | 1818 | 0.000 |
Why?
|
Fluorouracil | 1 | 1989 | 1642 | 0.000 |
Why?
|
Mitotic Index | 1 | 1984 | 162 | 0.000 |
Why?
|
Cyclophosphamide | 1 | 1989 | 2219 | 0.000 |
Why?
|
Mice, Nude | 1 | 1990 | 3604 | 0.000 |
Why?
|
Europe | 1 | 1989 | 3422 | 0.000 |
Why?
|
Doxorubicin | 1 | 1989 | 2224 | 0.000 |
Why?
|
Methotrexate | 1 | 1989 | 1717 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 1999 | 14607 | 0.000 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1983 | 880 | 0.000 |
Why?
|
Clinical Trials as Topic | 2 | 1987 | 8000 | 0.000 |
Why?
|
Hemadsorption | 1 | 1980 | 7 | 0.000 |
Why?
|
Receptors, Concanavalin A | 1 | 1980 | 11 | 0.000 |
Why?
|
Cytochalasin B | 1 | 1980 | 74 | 0.000 |
Why?
|
Concanavalin A | 1 | 1980 | 190 | 0.000 |
Why?
|
Brachytherapy | 1 | 1988 | 1223 | 0.000 |
Why?
|
Hyaluronoglucosaminidase | 1 | 1980 | 136 | 0.000 |
Why?
|
Microbial Collagenase | 1 | 1980 | 112 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1996 | 8529 | 0.000 |
Why?
|
Trypsin | 1 | 1980 | 486 | 0.000 |
Why?
|
Mice | 3 | 1996 | 81324 | 0.000 |
Why?
|
Colchicine | 1 | 1980 | 258 | 0.000 |
Why?
|
Disease Progression | 1 | 1995 | 13506 | 0.000 |
Why?
|
Surface Properties | 1 | 1980 | 1162 | 0.000 |
Why?
|
Bone Neoplasms | 1 | 1989 | 2527 | 0.000 |
Why?
|
Reoperation | 1 | 1987 | 4304 | 0.000 |
Why?
|
Patient Care Team | 1 | 1987 | 2513 | 0.000 |
Why?
|
Radiography | 1 | 1987 | 6975 | 0.000 |
Why?
|
Signal Transduction | 1 | 1996 | 23415 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 1986 | 13630 | 0.000 |
Why?
|